Return of granulocyte transfusions

Current Opinion in Pediatrics

Volumn 12, Issue 1, 2000, Pages 18-22

  Dale, David C ^a   Liles, W Conrad ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ALLOIMMUNIZATION; APPETITE DISORDER; BLOOD DONOR; BONE PAIN; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; GRANULOCYTE TRANSFUSION; HEADACHE; HUMAN; INFECTION; INSOMNIA; LEUKAPHERESIS; LUNG TOXICITY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; REVIEW;

CHILD; DEXAMETHASONE; DRUG THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE TRANSFUSION; NEOPLASMS; NEUTROPENIA;

EID: 0033968605     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200002000-00004     Document Type: Review

References (34)

1. 1 Bensinger W, Price T, Dale D, Appelbaum F, Clift R, Lilleby K, et al.: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993, 81:1883-1888. This study was the first to establish the marked improvement in granulocyte collection and posttransfusion increments that can be achieved by G-CSF treatment of donors.
2. 2 Casper C, Seger R, Burger J, Gmur J: Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993, 81:2866-2871.
3. 3 Dale D, Liles W, Summer W, Nelson S: Review: granulocyte colony-stimulating factor: role and relationships in infectious diseases. J Infect Dis 1995, 72:1061-1075.
4. 4 Price T: Granulocyte colony-stimulating factor-mobilized granulocyte concentrate transfusions. Curr Opin Hematol 1998, 5:392-395.
5. 5 Fetscher S, Mertelsmann R: Supportive care in hematologic malignancies. Curr Opin Hematol 1998, 5:271-286.
6. 6 Schiffer C: Granulocyte transfusion therapy. Curr Opin Hematol 1999, 6:3-7.
7. 7 Price TH, Bowden RA, Boeckh M, Liles WC, Llewellyn C, Fuller F, Dale DC: Neutrophil collection from community apheresis donors after granulocyte colony-stimulating factor and dexamethasone stimulation: feasibility and efficacy [abstract]. Blood 1997, 90:137.
8. 8 Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC: A comparative trial of granulocyte colony-stimulating factor (G-CSF) and dexamethasone alone and in combination for the mobilization of neutrophils in the peripheral blood of normal human volunteers. Transfusion 1997, 37:182-187.
9. 9 Jendiroba D, Lichtiger B, Anaissie E, Reddy V, O'Brien S, Kantarjian H, Freireich E: Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion 1998, 38:722-728.
10. 10 Lee J, Leitman S, Klein H: A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. Blood 1995, 86:4662-4666. This important study reaffirms the value of starch to aid in the collection of granulocytes.
11. 11 Adkins D, Ali S, Despotis G, Dynis M, Goodnough L: Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte-colony-stimulating factor. Transfusion 1998, 38:557-564. This valuable study examines the details of granulocyte collection.
12. 12 Lane T, Ho A, Bashey A, Peterson S, Young D, Law P: Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage-and granulocyte-colony-stimulating factors. Transfusion 1999, 39:39-47.
13. 13 Anderlini P, Donato M, Chan K, Huh Y, Gee A, Lauppe M, et al.: Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999, 39:555-560.
14. 14 Stroncek D, Clay M, Jaszcz W, Lennon S, Smith J, McCullough J: Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 1999, 9:37-50. This important study examines many laboratory variables after short-term G-CSF treatment.
15. 15 Froberg M, Garg U, Stroncek D, Geis M, McCullough J, Brown D: Changes in serum osteocalcin and bone-specific alkaline phosphates are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion 1999, 39:410-414.
16. 16 Schuld A, Mullington J, Hermann D, Hinze-Selch D, Fenzel T, Holsboer F, Pollmacher T: Effects of granulocyte colony-stimulating factor on night sleep in humans. Am J Physiol 1999, 276:1149-1155. This interesting study provides new insights into the nonhematologic effects of G-CSF.
17. 17 Rutella S, Rumi C, Lucia M, Sica S, Cauda R, Leone G: Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness. Exp Hematol 1998, 26:1024-1033.
18. 18 Volk E, Domen R, Smith M: An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med 1999, 123:508-513. This important review of ethical issues raises questions but leaves most of them to be answered in the future.
19. 19 Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al.: Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997, 90:903-908.
20. 20 Cleaver S, Goldman J: Use of G-CSF to mobilise PBSC in normal healthy donors: an international survey. Bone Marrow Transplant 1998, 21(Suppl 3):29-31. This key survey reveals the uncertainty and variability of practices in the treatment of healthy donors of blood products.
21. 21 Freedman M: Safety and long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol 1997, 4:217-224.
22. 22 Stroncek D, Clay M, Herr G, Smith J, Ilstrup S, McCullough J: Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the result of a second mobilization and collection. Transfusion 1997, 37:304-308.
23. 23 Falang A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al.: Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999, 93:2506-2514.
24. 24 Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Taparkou A, Tzimouli V, Tsandali H, Kremenopoulos G: Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr 1998, 157:583-588.
25. 25 Stroncek D, Jaszcz W, Herr G, Clay M, McCullough J: Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor. Transfusion 1998, 38:663-668. This excellent report provides detailed information on the expression of several neutrophil antigens before, during, and after G-CSF administration.
26. 26 Gaviria J, van Burik J, Dale D, Root R, Liles W: Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999, 179:1038-1041.
27. 27 Gaviria J, van Burik J, Dale D, Root R, Liles W: Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis 1999, 179:1301-1304.
28. 28 Dale D, Liles W, Llewellyn C, Rodger E, Price T: Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion 1998, 38:713-721. This important study establishes that neutrophils from donors pretreated with G-CSF and dexamethasone have a long blood half life and can migrate to sites of inflammation.
29. 29 Dalhoff K, Hansen F, Dromann D, Schaaf B, Aries S, Braun J: Inhibition of neutrophil apoptosis and modulation of the inflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers. J Infect Dis 1998, 178:891-895.
30. 30 Dignani M, Anaissie E, Hester J, O'Brien S, Vartivarian S, Rex J, et al.: Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11:1621-1630.
31. 31 Di Mario A, Sica S, Salutari P, Ortu La Babera E, Marra R, Leone G: Granulocyte colony-stimulating factor-primed leukocyte transfusions in Candida tropicalis fungemia in neutropenic patients. Haematologica 1997, 82:362-363.
32. 32 Catalano L, Fontana R, Scarpato N, Picardi M, Rocco S, Rotoli B: combined treatment with amphotericin-B and granulocyte transfusion from G-CSF - stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica 1997, 82:71-72.
33. 33 Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, et al.: Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998, 15:2719-2724.
34. 34 Stroncek DF: Neutrophil antibodies. Curr Opin Hematol 1997, 4:455-458.